Izumi Oosuka1, Yoshiaki Tanaka2, Naoyoshi Miura2
and Korehito Yamanouchi1,*
1Laboratory of Neuroendocrinology, Department of Basic Human Sciences, School of Human Sciences, Waseda University,
2-579-15, Mikajima, Tokorozawa, Saitama 359-1192, Japan
2Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., 2512-1, Oshikiri, Konan-machi, Osato-gun, Saitama 360-0111, Japan
* To whom all correspondence should be addressed.
Abstract: The effects of a prolylendopeptidase inhibitor, 1-[3-(2-indanylanylacetyl)-L-thioprolyl]pyrrolidine (Z-321), on lordosis behavior were investigated in estrogen and progesterone-treated ovariectomized rats. Females were orally administered 100, 200 or 300 mg/kg Z-321 or the vehicle (control). The mean lordosis quotient in the rats given 300 mg/kg Z-321 was lower than that in control group, but that in rats given 100 or 200 mg/kg Z-321 was not lower. Thus, Z-321 suppressed lordosis in estrogen and progesterone-treated ovariectomized rats. Peptide neurotransmitters, especially those containing proline, are thought to be involved in the inhibitory mechanisms for lordosis behavior.
Keywords: Prolylendopeptidase inhibitor, Peptide neurotransmitter, Lordosis